I last reviewed Mastercard (MA) in my June 8, 2023 guest post at Dividend Power. At the time, the most recently available financial results were for Q1 2023. Now, based on my analysis of Q4 and FY2023 results and FY2024 outlook that were released on January 31, I conclude that Mastercard is unreasonably valued. In [...]
I initiated a West Pharmaceutical (WST) position on November 25, 2022 with the purchase of 100 shares @ ~$225 in a 'Core' account within the FFJ Portfolio. I would have acquired more shares but we had just closed the purchase of an additional property which put a dent in my liquidity. By the time I [...]
On February 15, my Can CosMc’s Improve McDonald’s Results? guest post was published at Dividend Power. McDonald's (MCD) has repeatedly boasted about its ability to raise menu prices without negatively impacting sales. A sizable segment of its customer base, however, is the lower income consumer. People can only put up with so much. Some are [...]
I remain cautious in the current environment and am not looking to aggressively (1) initiate new positions and (2) increase my exposure to exiting holdings. Markets operate in cycles and inevitably, a major event or a series of events will trigger a broad market correction. While I do not invest in the broad market, the [...]
Intercontinental Exchange (ICE) has an enviable growth track record having just reported its 18th consecutive year of record revenues, operating income, and adjusted EPS. I last reviewed ICE in my October 5, 2023 guest post at Dividend Power. At the time, the most currently available results were for Q2 2023 (as of June 30). With [...]
I last reviewed S&P Global (SPGI) in my November 3 post following the release of Q3 and YTD2023 results on November 2. Using the recently released Q4 and FY2023 results and FY2024 guidance, I remain of the opinion that wide moat S&P Global is too richly valued. Business Overview Until such time as the FY2023 [...]
I last reviewed Paycom Software (PAYC) in my November 2, 2023 post following the release of Q3 and YTD2023 results. Despite reasonably good results, they fell short of the company's guidance range as a result of lower-than-expected service revenues and unscheduled payroll runs. Investors did not respond well and punished PAYC's share price. Following the [...]
In my November 14, 2023 Buy Thermo Fisher (TMO) While It Faces Short Term Headwinds post, I state the time to invest in great companies is when they face temporary headwinds and fall out of favor with many investors. In my December 8 guest post at Dividend Power, I conclude that TMO was still fairly [...]
I initiated a Nasdaq (NDAQ) position with the purchase of 500 shares in a 'Core' account within the FFJ Portfolio on June 12, 2023 at ~$51/share and disclosed my rationale for doing so in this June 13, 2023 post. I subsequently acquired another 100 shares at ~$50.75 on July 19 and disclosed this purchase in [...]
On January 31, Fortive (FTV), a Danaher (DHR) spin-off, released its Q4 and FY2023 results and FY2024 outlook. I last reviewed FTV in this October 31, 2023 post at which time the Q3 and YTD2023 had recently been released. In addition to analyzing FTV's current results, I looked at material FTV presented at its 2023 [...]